Method for the vaccination against hiv

A method for reducing and/or delaying pathological effects of human immunodeficiency virus I (HIV) or for reducing the risk of developing acquired immunodeficiency syndrome (AIDS) in a human infected with HIV, the method comprising the steps of:

• a) measuring in a biological sample, such as serum or plasma, from a human infected with HIV the amount of antibodies against one or more epitope of HIV envelope glycoproteins gp120 and/or gp41 in a suitable assay;
• b) selecting a subgroup of humans from a), wherein the amount of said measured antibodies corresponds to an amount above background level in uninfected humans and below 1 μg/ml of antibodies against Vacc-C5 in serum as measured by an ELISA assay as described in Example 33;
• c) treating said humans infected with HIV selected under b) with a compound that stimulate a humoral response in a subject;
• d) optionally having a maturation period, such as a period of up to 4 weeks;
• e) optionally repeating the measurement in a) and selecting humans infected with HIV, wherein the amount of said measured antibodies corresponds to an amount of above background level of uninfected humans, such as above 1 μg/ml of antibodies against Vacc-C5 in serum as measured by an ELISA assay as described in example 33;
• f) treating said humans infected with HIV selected under b) or e) with one or more peptides to stimulate a cell-mediated immune response and/or a compound that stimulate a humoral response in said human.